Pharmacist (Private / Compounding Practice) Tax Playbook

The Pharmacist Tax Landscape

Independent pharmacists and compounding pharmacy owners face a tax environment shaped by the SSTB limitation on the QBI deduction, significant inventory costs, regulatory compliance expenses, and the economics of the pharmaceutical dispensing business. Net income typically ranges from $100,000 to $400,000 for an independent pharmacy owner, with compounding pharmacy specialists earning $200,000–$500,000+.

The SSTB analysis for pharmacists is nuanced. A pharmacist who owns and operates a retail pharmacy (dispensing prescriptions, selling OTC products) may or may not be an SSTB depending on whether the primary income is from the sale of products (not SSTB) or from professional services (SSTB). A compounding pharmacist who primarily provides professional compounding services is more likely to be classified as an SSTB. Practitioners should analyze the income mix for each pharmacy client.

The S-Corp election is the primary SE tax reduction tool for pharmacist practice owners with net income above $80,000. With a $120,000 reasonable salary and $250,000 in net income, the S-Corp saves approximately $12,000 in FICA taxes annually. The S-Corp also enables a Solo 401(k) with employer contributions based on W-2 wages.

SSTB Analysis for Pharmacists

The SSTB classification for pharmacists depends on the nature of the practice. Health is an SSTB under §199A(d)(1)(A), defined as "the performance of services in the field of health, including physicians, pharmacists, nurses, dentists, veterinarians, physical therapists, psychologists, and other similar healthcare professionals." Pharmacists are specifically listed as an SSTB.

However, the SSTB rules have a de minimis exception: if less than 10% of gross receipts come from SSTB activities (for businesses with gross receipts under $25M), the entire business is treated as non-SSTB. A retail pharmacy that derives 90%+ of revenue from product sales (prescriptions, OTC products) and less than 10% from professional services (consultations, compounding) may qualify as non-SSTB under the de minimis rule.

Inventory and COGS for Pharmacy Owners

Prescription drug inventory is the largest asset on a pharmacy's balance sheet. The cost of drugs dispensed is deducted as COGS when the prescriptions are filled, not when the drugs are purchased. The pharmacy must maintain accurate dispensing records to support the COGS deduction. The FIFO method is most common for pharmacy inventory; LIFO is available but rarely used because drug prices tend to decline over time (generic substitution).

Drug waste and expired inventory are deductible as ordinary business losses under §165. The pharmacy must document the disposal of expired drugs in compliance with DEA and state pharmacy board regulations. The documentation serves both regulatory and tax purposes.

Regulatory Compliance Costs

Independent pharmacies face significant regulatory compliance costs: DEA registration ($888/year for a Schedule II dispenser), state pharmacy board license fees, PCAB accreditation for compounding pharmacies, and USP 797/800 compliance costs for sterile compounding facilities. All of these costs are deductible as ordinary business expenses under §162.

The cost of a sterile compounding cleanroom (HVAC upgrades, ISO-classified clean rooms, laminar flow hoods) qualifies for bonus depreciation under §168(k) if the equipment has a recovery period of 20 years or less. Structural components of the cleanroom (walls, floors, ceilings) are 39-year property and must be depreciated over 39 years unless a cost segregation study reclassifies them as shorter-lived property.

Frequently Asked Questions